Wegovy Pregnancy & Lactation Safety: What the Evidence Actually Shows

Wegovy is the brand name for semaglutide 2.4 mg once weekly, a GLP-1 receptor agonist FDA-approved for chronic weight management. The same active ingredient, semaglutide, is sold as Ozempic (1 or 2 mg) for type 2 diabetes; the pregnancy guidance below applies to semaglutide regardless of brand or dose. Per the current FDA label, Wegovy is contraindicated during pregnancy based on animal reproduction studies showing embryofetal harm at clinically relevant exposures, and the label recommends stopping the drug at least two months before a planned pregnancy [1]. No controlled human pregnancy trials exist, so the actual human risk is unquantified rather than proven low or high. Breastfeeding is not recommended during treatment because it is unknown whether semaglutide passes into human milk [1].

Why pregnancy changes the risk-benefit calculus

Semaglutide slows gastric emptying, reduces hypothalamic appetite signaling, and enhances glucose-dependent insulin secretion [1]. In the STEP 1 trial, participants on semaglutide 2.4 mg lost a mean 14.9% of body weight at 68 weeks versus 2.4% on placebo, with nausea in 44% and vomiting in about 25% of the semaglutide group [2]. That degree of appetite suppression and caloric deficit is what makes the drug effective for weight management, and it is also what makes it a poor fit for pregnancy, which requires an estimated additional 340 kcal/day in the second trimester and about 450 kcal/day in the third to support fetal growth and maternal physiologic changes [3].

What the animal reproduction data actually show

No human randomized trials have enrolled pregnant women, so the FDA's contraindication rests on preclinical toxicology. In rat studies during organogenesis, semaglutide exposures around half the human exposure at the maximum recommended dose were associated with increased embryofetal mortality and skeletal malformations (vertebral and rib abnormalities) [1]. In rabbits, exposure during organogenesis at similar or lower multiples was associated with early pregnancy loss and a small increase in visceral abnormalities [1]. This signal appeared at exposures close to clinical dosing rather than only at extreme, supratherapeutic doses, which is part of why the FDA uses a contraindication rather than a weaker "use only if benefit outweighs risk" statement [1].

Other GLP-1 receptor agonists approved for weight management, including liraglutide (Saxenda) and tirzepatide (Zepbound), carry comparable pregnancy warnings based on similar animal toxicology, suggesting this is a class-level signal rather than a semaglutide-specific one [4][5]. ACOG's Practice Bulletin on obesity in pregnancy discusses discontinuing anti-obesity pharmacotherapy before conception given the lack of human safety data for newer agents, though readers should consult the current bulletin directly for its exact wording on GLP-1 receptor agonists specifically, since agent-by-agent language in professional guidance changes as new drugs reach market [3].

The two-month washout: what it is based on, and its limits

Semaglutide's elimination half-life is approximately one week. Five half-lives, the standard benchmark for near-complete drug clearance, works out to roughly 35 days. The FDA's two-month recommendation builds in an additional margin beyond that pharmacokinetic minimum [1]. This washout figure is a regulatory recommendation, not a guarantee that residual drug at day 60 is zero or that any exposure after that point carries a defined risk level; it reflects a labeling judgment under uncertainty, not a trial-confirmed safety threshold.

A separate practical issue: women with obesity or PCOS who lose meaningful weight on Wegovy often see improved ovulatory function [7]. Fertility can return or increase during treatment, sometimes before a patient has decided she is ready to conceive. This is a reason contraception counseling should happen at treatment initiation, not only when pregnancy becomes a stated goal.

What to do if pregnancy occurs during treatment

Unplanned pregnancies do occur during Wegovy treatment. If a patient discovers she is pregnant while taking it, current label guidance is to stop the drug and contact the prescriber; exposure by itself is not stated as an indication for pregnancy termination [1]. Reasonable follow-up includes standard prenatal care, a detailed anatomy ultrasound around 18 to 20 weeks, and referral to maternal-fetal medicine if the exposure window overlapped with organogenesis (roughly weeks 3 through 8 post-conception).

Human outcome data on first-trimester GLP-1 receptor agonist exposure remain sparse. One retrospective cohort study using insurance claims identified 110 pregnancies with first-trimester GLP-1 receptor agonist exposure (semaglutide and liraglutide combined) and found a major congenital malformation rate of 5.2% versus 3.3% in a matched unexposed cohort, a difference that did not reach statistical significance (adjusted OR 1.50, 95% CI 0.63 to 3.57) [10]. The study was small and underpowered to detect anything short of a large effect, and its authors did not present it as evidence of safety. This is the honest state of the human evidence: not reassuring, not alarming, genuinely inadequate to answer the question either way. MotherToBaby (OTIS) maintains a voluntary pregnancy exposure registry for GLP-1 receptor agonists that clinicians can use to report cases and that may eventually generate better-powered data [9].

Should you breastfeed while taking Wegovy?

Current guidance is not to breastfeed while on Wegovy, because it is unknown whether semaglutide enters human milk in clinically meaningful amounts. In lactating rats, semaglutide and its metabolites appeared in milk at concentrations roughly 3 to 12 times lower than maternal plasma levels, but animal milk-transfer data do not reliably predict human infant exposure [1]. The FDA label states plainly that there are no data on semaglutide's presence in human milk, its effects on a breastfed infant, or its effects on milk production [1]. LactMed lists semaglutide with a recommendation to consider alternatives during lactation given the absence of human data [11].

There is also a plausible, unproven mechanistic concern separate from direct infant exposure: lactation requires an estimated additional 450 to 500 kcal/day, and a drug that reduces caloric intake by the magnitude seen in trials could theoretically affect milk supply [3]. This has not been directly studied in breastfeeding women and should be treated as a hypothesis, not an established effect.

Weight management during and after pregnancy without a GLP-1

Discontinuing Wegovy does not mean abandoning weight goals. Institute of Medicine gestational weight gain targets, referenced in ACOG guidance, are stratified by pre-pregnancy BMI [3]:

• BMI under 18.5: 28 to 40 lbs
• BMI 18.5 to 24.9: 25 to 35 lbs
• BMI 25.0 to 29.9: 15 to 25 lbs
• BMI 30.0 or above: 11 to 20 lbs

Medical nutrition therapy, structured activity, and behavioral counseling remain first-line during pregnancy for women with pre-pregnancy obesity [3]. Metformin, used off-label for gestational diabetes management in some protocols, has a longer human pregnancy safety track record than GLP-1 receptor agonists, though it is not FDA-approved for weight management [12].

Weight regain after stopping a GLP-1 receptor agonist is well documented outside of pregnancy: in the STEP 1 extension analysis, participants regained roughly two-thirds of lost weight within a year of stopping semaglutide [13]. That pattern is a reason to build a postpartum weight plan before discontinuing, not a reason to continue the drug through pregnancy.

Contraception while on Wegovy: a practical gap

Semaglutide's effect on gastric emptying could theoretically slow absorption of oral medications, including combined oral contraceptives. The FDA label notes this pharmacokinetic possibility but states that formal studies did not identify a clinically significant interaction with commonly used oral co-medications [1]. Even so, during dose escalation, when nausea and vomiting are most common, absorption of any oral pill could be less reliable in practice. Clinicians may reasonably discuss non-oral contraception (IUD, implant, patch, or injectable) for patients who want the highest reliability while on treatment, particularly since fertility can improve unexpectedly with weight loss [7].

The fertility paradox

Obesity is an established contributor to anovulatory infertility, and weight loss of even 5 to 10% can restore ovulation in some women with obesity-related anovulation or PCOS [7]. This creates a genuine tension: the treatment that improves fertility is the one that must be stopped, with a two-month lead time, before conception. A workable clinical approach is to set contraception and a target weight or metabolic goal at the start of treatment, then plan the transition off Wegovy well before a patient intends to try to conceive, rather than waiting until pregnancy is imminent.

Wegovy pregnancy-planning decision framework

This framework does not replace individualized prescribing decisions. It lays out the recurring scenarios and what the evidence above supports for each.

Comparing anti-obesity medications in pregnancy

No anti-obesity medication is FDA-approved for use during pregnancy, but the basis for concern differs by drug. Orlistat's labeling reflects concerns about reduced absorption of fat-soluble vitamins (A, D, E, K) important for fetal development; note that "Pregnancy Category X" is legacy FDA terminology from a system retired around 2015 and current labels use narrative risk summaries instead [16]. Phentermine-topiramate (Qsymia) carries a documented human signal: topiramate is associated with an increased rate of oral clefts compared with background population risk, and Qsymia is contraindicated in pregnancy with a REMS program requiring monthly pregnancy testing; readers should consult the current Qsymia label directly for the specific rate figures rather than relying on a secondhand number [17].

Semaglutide's pregnancy contraindication, by contrast, rests on animal toxicology rather than a confirmed human teratogenic signal. That is not the same as being safer. It reflects a thinner human evidence base, and a thin evidence base is not evidence of low risk.

What is established, what is plausible, and what is not established

Established: semaglutide causes embryofetal harm in rat and rabbit reproduction studies at exposures near the human therapeutic dose, and the FDA contraindicates Wegovy in pregnancy on that basis, with a recommended two-month discontinuation window before conception [1].

Plausible but unproven: that reduced caloric intake on Wegovy could impair milk supply during lactation; that the class-wide animal signal generalizes directly to human risk at a similar magnitude; that the two-month washout is the precise minimum needed rather than a conservative round number [1][3].

Not established: the actual rate of human birth defects or pregnancy loss associated with first-trimester semaglutide exposure, since the only cohort data available are small and statistically underpowered [10]. Whether semaglutide enters human breast milk at all, and if so at what concentration, is also not established [1][11].

This article is pending qualified clinical review. It is intended for general education and should not substitute for individualized guidance from an obstetric or prescribing clinician. Anyone taking Wegovy who is pregnant, trying to conceive, or breastfeeding should discuss timing and alternatives directly with their care team, and seek urgent care for any pregnancy complication regardless of medication history.